166 related articles for article (PubMed ID: 19428316)
1. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
De Francia S; D'Avolio A; De Martino F; Pirro E; Baietto L; Siccardi M; Simiele M; Racca S; Saglio G; Di Carlo F; Di Perri G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jun; 877(18-19):1721-6. PubMed ID: 19428316
[TBL] [Abstract][Full Text] [Related]
2. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
D'Avolio A; Simiele M; De Francia S; Ariaudo A; Baietto L; Cusato J; Fava C; Saglio G; Di Carlo F; Di Perri G
J Pharm Biomed Anal; 2012 Feb; 59():109-16. PubMed ID: 22036594
[TBL] [Abstract][Full Text] [Related]
3. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.
Pirro E; De Francia S; De Martino F; Fava C; Ulisciani S; Cambrin GR; Racca S; Saglio G; Di Carlo F
J Chromatogr Sci; 2011; 49(10):753-7. PubMed ID: 22080802
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
Kralj E; Trontelj J; Pajič T; Kristl A
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 903():150-6. PubMed ID: 22857863
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Andriamanana I; Gana I; Duretz B; Hulin A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906
[TBL] [Abstract][Full Text] [Related]
8. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
Moreno JM; Wojnicz A; Steegman JL; Cano-Abad MF; Ruiz-Nuño A
Biomed Chromatogr; 2013 Apr; 27(4):502-8. PubMed ID: 23034891
[TBL] [Abstract][Full Text] [Related]
9. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection.
Miura M; Takahashi N; Sawada K
J Chromatogr Sci; 2011 May; 49(5):412-5. PubMed ID: 21549035
[TBL] [Abstract][Full Text] [Related]
10. Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma.
Hsieh Y; Galviz G; Zhou Q; Duncan C
Rapid Commun Mass Spectrom; 2009 May; 23(9):1364-70. PubMed ID: 19337981
[TBL] [Abstract][Full Text] [Related]
11. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Titier K; Picard S; Ducint D; Teilhet E; Moore N; Berthaud P; Mahon FX; Molimard M
Ther Drug Monit; 2005 Oct; 27(5):634-40. PubMed ID: 16175138
[TBL] [Abstract][Full Text] [Related]
12. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
Birch M; Morgan PE; Handley S; Ho A; Ireland R; Flanagan RJ
Biomed Chromatogr; 2013 Mar; 27(3):335-42. PubMed ID: 22886846
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study.
Thappali SR; Varanasi KV; Veeraraghavan S; Vakkalanka SK; Khagga M
Arzneimittelforschung; 2012 Dec; 62(12):624-30. PubMed ID: 23138519
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection.
Yokoyama Y; Nozawa E; Morita M; Ishikawa E; Mori T; Sakurai M; Kikuchi T; Matsuki E; Yamazaki R; Kataoka K; Jibiki A; Kawazoe H; Suzuki S; Nakamura T
J Clin Lab Anal; 2022 Aug; 36(8):e24598. PubMed ID: 35819095
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
17. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N
Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839
[TBL] [Abstract][Full Text] [Related]
18. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Parker WT; Lawrence RM; Ho M; Irwin DL; Scott HS; Hughes TP; Branford S
J Clin Oncol; 2011 Nov; 29(32):4250-9. PubMed ID: 21990409
[TBL] [Abstract][Full Text] [Related]
19. Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry.
Zhang M; Moore GA; Fernyhough LJ; Barclay ML; Begg EJ
Anal Bioanal Chem; 2012 Oct; 404(6-7):2091-6. PubMed ID: 22865010
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]